GSK137647A is primarily used in research settings as a selective agonist for the free fatty acid receptor 4 (FFA4), also known as GPR120. It is widely utilized in studies aimed at understanding the role of FFA4 in various physiological processes, particularly in metabolic regulation and inflammation. Researchers employ this compound to explore its potential effects on insulin sensitivity, glucose homeostasis, and anti-inflammatory pathways, which are relevant to conditions like type 2 diabetes and obesity. Additionally, GSK137647A helps in investigating the signaling mechanisms of FFA4 and its interaction with other metabolic pathways, providing insights into potential therapeutic targets for metabolic disorders.